Antizyme inhibitor 2 (AZIN2) associates with better prognosis of head and neck minor salivary gland adenoid cystic carcinoma

dc.contributor.authorHämetoja Hanna
dc.contributor.authorAndersson Leif C
dc.contributor.authorMäkitie Antti
dc.contributor.authorBäck Leif
dc.contributor.authorHagström Jaana
dc.contributor.authorHaglund Caj
dc.contributor.organizationfi=hammaslääketieteen laitos|en=Institute of Dentistry|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.64787032594
dc.converis.publication-id66407951
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/66407951
dc.date.accessioned2022-10-28T13:18:37Z
dc.date.available2022-10-28T13:18:37Z
dc.description.abstractThe key regulator of the polyamine biosynthetic pathway is ornithine decarboxylase (ODC). ODC is activated by antizyme inhibitor 1 (AZIN1) and 2 (AZIN2). AZIN1 and recently AZIN2 have been related to cancer; however, their functions in adenoid cystic carcinoma (ACC) have not been studied. We performed immunohistochemical study on minor salivary and mucous gland ACC tissue samples of patients treated at the Helsinki University Hospital (Helsinki, Finland) during 1974-2012. We scored AZIN1 and 2 immunoexpression in 42 and 45 tumor tissue samples, respectively, and correlated them with clinicopathological factors and survival. Enhanced AZIN2 expression was associated with better survival. In addition, both AZINs were seen more commonly in cribriform and tubular than in solid growth patterns. AZIN1 expression did not correlate with the studied clinicopathological factors. It seems that AZIN2 expression is higher in cancer tissue with secretory functions. In ACC tissue, high AZIN2 expression could be related to well-differentiated histological type which still has a functioning vesicle transportation system. Thus, AZIN2 could be a prognostic factor for better survival of ACC patients.
dc.format.pagerange503
dc.format.pagerange511
dc.identifier.jour-issn0903-4641
dc.identifier.olddbid181206
dc.identifier.oldhandle10024/164300
dc.identifier.urihttps://www.utupub.fi/handle/11111/37572
dc.identifier.urlhttps://doi.org/10.1111/apm.13158
dc.identifier.urnURN:NBN:fi-fe2021093048674
dc.language.isoen
dc.okm.affiliatedauthorHagström, Jaana
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline313 Dentistryen_GB
dc.okm.discipline313 Hammaslääketieteetfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherWILEY
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1111/apm.13158
dc.relation.ispartofjournalAPMIS
dc.relation.issue8
dc.relation.volume129
dc.source.identifierhttps://www.utupub.fi/handle/10024/164300
dc.titleAntizyme inhibitor 2 (AZIN2) associates with better prognosis of head and neck minor salivary gland adenoid cystic carcinoma
dc.year.issued2021

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
apm.13158.pdf
Size:
647.88 KB
Format:
Adobe Portable Document Format
Description:
Publisher's pdf